Campaign
ProVascTec
Cell Therapy / BioTech
EIIS
A UCC spin-out which developed a novel mechanism for the efficient delivery of cell therapies for the treatment of patients suffering from blocked lower-leg arteries.
€
900,000 Funding goal
€
1,023,128 Invested
171Investors
Company Summary :
- An outstanding, multi-PhD Founding Team
- A MedTech spin-out from UCC
- Patent-protected technology (already granted in Europe and the USA)
- Global market size of $20 billion
- An Enterprise Ireland High Potential Start-Up company
- Already received €100,000 from NLC ventures (a Dutch-based venture capital firm)
- Qualifies for a 50% EIIS Tax Refund for private investors
- A pre-money Valuation of €5.3m
- NLC Ventures investing again in this round on the exact same terms as private investors
- Potential for 30X return on your investment